Abliva

Abliva
About Us
Contacts
Change country

Follow us:
Share:
Subscribe:

About Us

Abliva – Delivering mitochondrial healthAbliva discovers and develops medicines for the treatment of mitochondrial disease. This rare and often very severe disease occurs when the cell’s energy provider, the mitochondria, do not function properly. The company has prioritized two projects. KL1333, a powerful regulator of the essential co-enzymes NAD⁺ and NADH, has entered late-stage development. NV354, an energy replacement therapy, has completed preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).

Contacts

Catharina Johansson

CFO, IR & Communications

Medicon Village 223 81 Lund Sweden
+46 (0)46-275 62 21
http://www.abliva.com
ir@abliva.com

Abliva
+46 (0)46 275 62 20
info@abliva.com

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Newsletter June 2019

Thu, Jun 20, 2019 10:00 CET

Open attached PDF file to read the full newsletter. In this issue: · KL1333 in clinical study – how does it work? Interview with Matilda Hugerth · Exclusive agreement with Oroboros Instruments · New on the Board – Interview with Magnus Persson Read more about us at www.neurovive.com Follow us on LinkedIn View our videos, interviews and presentations by subscribing to our YouTube channel

There are no items matching the current filter

There are no more items matching the current filter

Share

About Us

Contacts

Newsletter June 2019

Subscribe